AstraZeneca – Research-Based BioPharmaceutical Company, global pharm.#Global #pharm


Posted On Jan 18 2018 by

global pharm

This website uses cookies to help us give you the best experience when you visit.

By using this website you consent to our use of these cookies.

Find out more about how we use cookies and how to manage them by reading our cookie notice.

Global pharm Global pharm

Global pharm

  • What science can do
    • What science can do
    • LabTalk blog
    • Our technology
  • Our science
    • Our science
    • Pipeline
    • Publications
    • Cambridge
    • Gothenburg
    • Gaithersburg
    • IMED Biotech Unit
    • MedImmune
    • Global Medicines Development
  • Our focus areas
    • Cardiovascular and Metabolic Diseases
    • Oncology
    • Respiratory
    • Inflammation and Autoimmunity
    • Neuroscience
    • Infection and Vaccines
    • All focus areas
    • All medicines
  • Our company
    • Our company
    • Our strategy
    • Our people
    • Leadership team
  • Careers
    • Careers
    • Global careers site
  • Investors
    • Investor Relations
    • Stock Exchange announcements
    • Results and presentations
    • Annual Reports
    • Governance
    • Dividend policy
    • Debt Investors
    • Shareholder information
    • Key facts
    • FAQs
  • Partnering
    • Partnering
    • Partnering case studies
    • Get in touch
  • Media
    • Media centre
    • Image library
    • Broadcast videos
    • Articles
    • Press Releases
    • Archive
    • Medical Releases
  • Sustainability
    • Sustainability
    • Access to healthcare
    • Environmental protection
    • Ethics and transparency
  • More Hide
  • AstraZeneca Websites
  • Global site

Precision Medicine and Genomics: targeting innovative medicines to patients most likely to benefit

Directing CRISPR/Cas9 gene-editing using novel guides

Respiratory: Following the science to improve patient outcomes

Science is at the heart of everything we do.

Ground-breaking science

AstraZeneca’s progress in the immuno-oncology field fills me with great excitement! Our emerging data will help us to identify and validate patient biomarkers and potential therapeutic targets, which may enable better treatment decisions, as well as potentially providing novel opportunities with our advancing DNA Damage Response portfolio.

Helen Angell, Associate Principal Scientist, Oncology, Translational Sciences, IMED Biotech Unit

Publications

Our innovative science means a strong track-record of publication in peer-reviewed journals, contributing to the foundation of scientific advancement.

projects in our pipeline

CoLAB High Throughput Screening System

Our new facility in Cambridge will be an open, welcoming and vibrant centre

Fasenra (benralizumab) receives US FDA approval for severe eosinophilic asthma

Benralizumab receives positive EU CHMP opinion for severe, uncontrolled eosinophilic asthma

Our science

At AstraZeneca, science is at the core of everything we do. But more than that, science is who we are.

Career opportunities

There is an expanding universe of biological data available which can revolutionise our understanding of disease and therapy if we find innovative ways to share and explore it.

Jonathan Dry, Principal Scientist, Bioinformatics, Oncology, Innovative Medicines Early Development

Acoustic mass spectrometer platform

Three

strategic science centres

Our research sites are collaborative, innovative and dynamic environments that allow our scientists to keep pushing the boundaries

Inhibiting stages in the DNA damage response pathway

Our focus areas

Global pharm

Cardiovascular and Metabolic diseases

Global pharm

Global pharm

Global pharm

Inflammation and autoimmunity

Global pharm

Global pharm

Infection and Vaccines

AstraZeneca job search

At AstraZeneca we are guided in our work by a strong set of values, and we’re resetting expectations of what a bio-pharmaceutical company can be. If you’re inspired by the possibilities of science to make a difference and ready to discover what you can do – join us.

Start a career that will help improve life for millions.

Learn more about our School/College Student, Undergraduate, Graduate and Post Doctorate programmes with us in our Early Careers page.

Working at AstraZeneca

We need great people who share our passion for science and have the drive and determination to meet the unmet needs of patients around the world. Find out more about our teams and the work they do.

To partner with AstraZeneca

I often say being in Business Development is having the best job in AstraZeneca in terms of the motivation, interest and challenging work we do with incredibly smart people from science and business on projects that really make a difference for our partners and patients.

Shaun Grady, Vice-President Business Development Operations

Horizon Discovery and AstraZeneca: searching for novel, personalised cancer therapies

Partnering with us

We partner with like-minded organisations and pursue a range of different types of opportunities that are aligned with our portfolio and areas of expertise.

Open Innovation

Our Open Innovation platform is designed to foster open innovation partnerships spanning all stages of drug discovery and development.

AstraZeneca and Incyte enter clinical trial collaboration in early lung cancer

AstraZeneca and MSD rapidly advance Lynparza in Japan with a second regulatory submission

Collaborate with us

The best science doesn t happen in isolation.

Investor information

Our financial performance in the quarter was in line with expectations, reflecting good commercial execution, including strong growth in Emerging Markets with standout sales in China.

Pascal Soriot, Executive Director and Chief Executive Officer

Latest presentation

Year-To-Date and Q3 2017 results

Financial calendar

Find all the latest dates for ex-dividends, investor roadshows and more

See all the results and presentations

Stock exchange announcements

Find all the latest announcements from the stock exchange

Fasenra (benralizumab) receives US FDA approval for severe eosinophilic asthma

Benralizumab receives positive EU CHMP opinion for severe, uncontrolled eosinophilic asthma

Investors

Find out more about investing in AstraZeneca, everything from investor relations to dividend policies.

AstraZeneca Websites

This website is intended for people seeking information on AstraZeneca’s worldwide business. Our country sites can be located in the AZ Network.

Website Atlas ID: 1017655.011

Date of next review: October 2017

Resources

Quick links

Social Media

utility links

You are now leaving AstraZeneca.com

You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents.

AstraZeneca provides this link as a service to website visitors. AstraZeneca is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit.

Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed.


Last Updated on: January 18th, 2018 at 7:16 pm, by


Written by admin


Leave a Reply

Your email address will not be published. Required fields are marked *